Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Adult Acute Myeloid Leukemia with fus::ERG fusion: A national, retrospective, multi-center study

Xiaoxia Hu, Yunxiang Zhang, Jianfeng Li, Jingtao Huang, Shaowei Qiu, Anli Lai, Jia Chen, Xiao-Dong Mo, Huafeng Wang, Yanmin Zhao, Xiaoyu Zhu, Yang Cao, Ran Zhang, Weijie Cao, Yue Lu, Fang Zhou, Xiangqin Weng, Yongmei Zhu

Blood (2025) 146 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2025-1698

Published: 2025

Journal Articles

Molecular subtype combined with peripheral blast clearance rate to optimize the treatment of newly diagnosed Acute Myeloid Leukemia: Interim analysis of the multicenter, Phase II study (IA+X 2024)

Yunxiang Zhang, Hongming Zhu, Xiangqin Weng, Yongmei Zhu, Jiong Hu, Xiaoxia Hu, Qiusheng Chen, Ligen Liu, Junmin Li, Yang Shen

Blood (2025) 146 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2025-3436

Published: 2025

Journal Articles

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Blood (2025) 146 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2025-3391

Published: 2025

Journal Articles

QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis

Blood (2025) 146 (Supplement 1): 5205.

https://doi.org/10.1182/blood-2025-5205

Published: 2025

Journal Articles

Distinct prognosis and transplant timing in core-binding factor Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5297.

https://doi.org/10.1182/blood-2025-5297

Published: 2025

Journal Articles

High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Blood (2024) 144 (Supplement 1): 2882.

https://doi.org/10.1182/blood-2024-199412

Published: 2024

Journal Articles

Clinical Characteristics, Genetic Profile and Prognosis of Adult Acute Myeloid Leukemia with NUP98 Rearrangement

Hongming Zhu, Yubing Zhao, Wenyan Cheng, Xinjie Chen, Yunxiang Zhang, Jiong Hu, Junmin Li, Yang Shen

Blood (2023) 142 (Supplement 1): 2867.

https://doi.org/10.1182/blood-2023-178329

Published: 2023

Journal Articles

Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)

Yunxiang Zhang, Qiusheng Chen, Xiangqin Weng, Yang Shen, Wen Wu, Jiong Hu, Jie Hao, Ligen Liu, Junmin Li

Blood (2023) 142 (Supplement 1): 829.

https://doi.org/10.1182/blood-2023-179311

Published: 2023

Journal Articles

Modified Intensive Induction Treatment for Elderly Acute Myeloid Leukemia Patients Based on Peripheral Blast Clearance Rate: A Phase II Single-Arm Study

Ya Li, Xiaoyang Li, Hongming Zhu, Yunxiang Zhang, Yu Chen, Qiusheng Chen, Yu Zheng, Junmin Li

Blood (2021) 138 (Supplement 1): 1260.

https://doi.org/10.1182/blood-2021-152042

Published: 2021

Journal Articles

Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytie Leukemia with Different Risk Stratifications: A Interim Analysis of China APL 2012 Study

Blood (2016) 128 (22): 445.

https://doi.org/10.1182/blood.V128.22.445.445

Published: 2016

Journal Articles

Optimization of IA Regimen with Homoharringtonine for Induction in Younger AML Based on Peripheral Blast Clearance Rate: First Result of the RJ-AML 2014 Trial

Junmin Li, Prof., Yunxiang Zhang, Qiusheng Chen, Zhao Liu, Chen Yu, Jiong Hu, MD, Xiangqin Weng, Bing Chen, Saijuan Chen, Zhu Chen

Blood (2016) 128 (22): 3990.

https://doi.org/10.1182/blood.V128.22.3990.3990

Published: 2016

Journal Articles

The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia

Blood (2016) 128 (11): 1525–1528.

https://doi.org/10.1182/blood-2016-02-699439

Published: 2016

Includes: Supplemental data

Journal Articles

The Glasgow Prognostic Score (GPS) As a Significant Predictor of Diffuse Large B Cell Lymphoma Treated with the R-CHOP in China

Xiaoyang Li, Yunxiang Zhang, Hongming Zhu, Jiong Hu, Junmin Li, MD PhD

Blood (2014) 124 (21): 5398.

https://doi.org/10.1182/blood.V124.21.5398.5398

Published: 2014

Journal Articles

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Hongming Zhu, Jiong Hu, Li Chen, Wei Zhou, Xiaoyang Li, Wang Lining, Xia Zhao, Yunxiang Zhang, Huijin Zhao, Yu Chen, Huiping Sun, Qiusheng Chen, Yu Chen, Weili Zhao, Jianqing Mi, Zhixiang Shen, Saijuan Chen, Zhenyi Wang, Junmin Li, MD PhD

Blood (2014) 124 (21): 282.

https://doi.org/10.1182/blood.V124.21.282.282

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Adult Acute Myeloid Leukemia with fus::ERG fusion: A national, retrospective, multi-center study

Molecular subtype combined with peripheral blast clearance rate to optimize the treatment of newly diagnosed Acute Myeloid Leukemia: Interim analysis of the multicenter, Phase II study (IA+X 2024)

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis

Distinct prognosis and transplant timing in core-binding factor Acute Myeloid Leukemia

High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Clinical Characteristics, Genetic Profile and Prognosis of Adult Acute Myeloid Leukemia with NUP98 Rearrangement

Optimization of Idarubicin and Cytarabine Induction Regimen with Homoharringtonine for Newly Diagnosed AML Based on the Peripheral Blast Clearance Rate: First Result of the Multicenter, Randomized, Phase 3 Trial (RJ-AML 2016)

Modified Intensive Induction Treatment for Elderly Acute Myeloid Leukemia Patients Based on Peripheral Blast Clearance Rate: A Phase II Single-Arm Study

Retinoic Acid and Arsenic Trioxide with or without Chemotherapy for Acute Promyelocytie Leukemia with Different Risk Stratifications: A Interim Analysis of China APL 2012 Study

Optimization of IA Regimen with Homoharringtonine for Induction in Younger AML Based on Peripheral Blast Clearance Rate: First Result of the RJ-AML 2014 Trial

The 12-year follow-up of survival, chronic adverse effects, and retention of arsenic in patients with acute promyelocytic leukemia

The Glasgow Prognostic Score (GPS) As a Significant Predictor of Diffuse Large B Cell Lymphoma Treated with the R-CHOP in China

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only